S-1: Drugs Made In America II Corp. Files $500M SPAC IPO

Drugs Made In America Acquisition II Corp. files S-1 for a $500 million initial public offering to target pharmaceutical industry businesses.

Summary

• Drugs Made In America Acquisition II Corp. is a newly incorporated Cayman Islands exempted company, a blank check company formed to effect a business combination with one or more businesses.
• The company has not yet selected a target business nor initiated substantive discussions, but intends to focus its search on the pharmaceutical industry.
• The initial public offering consists of 50,000,000 units at $10.00 per unit, totaling $500,000,000.
• Each unit comprises one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon business combination.
• Underwriters have a 45-day option to purchase up to an additional 7,500,000 units.
• The sponsor, Drugs Made In America Acquisition II LLC, and Cantor Fitzgerald & Co. will purchase an aggregate of 1,200,000 private units at $10.00 per unit ($12,000,000 total) in a private placement.
• The company has 24 months from the closing of the offering to complete an initial business combination.
• If no business combination is completed within 24 months, 100% of public shares will be redeemed at approximately $10.00 per share, and rights will expire worthless.
• The management team, including CEO Lynn Stockwell and CFO Glenn Worman, has experience in the pharmaceutical industry and SPACs.
• The business strategy aims to identify, acquire, and grow a pharmaceutical company, focusing on mitigating U.S. medical supply chain risks by investing in domestic manufacturing of critical drugs and APIs.
• The post-business combination company aims for end-to-end capability from plant-based raw material production to drug manufacturing and direct patient delivery, targeting the estimated $44 billion plant-based production segment, API market, and generic medications.

Sentiment

Score: 4

Explanation: While the management team possesses relevant industry experience and a clear strategic focus on a critical sector (U.S. pharmaceutical supply chain), the inherent risks of a blank check company, particularly the substantial dilution for public shareholders from founder shares and potential conflicts of interest due to management's involvement in other SPACs, temper enthusiasm. The lack of an identified target and the competitive SPAC market also contribute to a cautious outlook.

Positives

• The management team possesses extensive experience and a broad network within the pharmaceutical industry, which is the company's target sector.
• The strategic focus on mitigating U.S. medical supply chain risks through on-shoring advanced domestic manufacturing for critical drugs and APIs aligns with national priorities.
• The company aims to create a fully integrated, competitive cost business with end-to-end capabilities from raw material production to drug manufacturing and direct patient delivery.
• The target market for plant-based production, API, and generic medications is estimated at $44 billion, indicating significant growth potential.
• The sponsor has agreed to indemnify the company against certain third-party claims that could reduce the trust account below $10.00 per public share, offering a layer of protection for public shareholders.

Negatives

• As a blank check company, there is no operating history, revenues, or identified target business, making it difficult to evaluate future performance.
• Public shareholders will experience immediate and substantial dilution, estimated at approximately 112.40% or $11.24 per share (assuming no over-allotment exercise and maximum redemption), due to the nominal price paid by the sponsor for founder shares.
• Management and directors have potential conflicts of interest due to their involvement with other entities, including another SPAC (Drugs Made In America Acquisition Corp. DMAA) also seeking business combination targets.
• The 24-month deadline to complete a business combination may give potential target businesses leverage in negotiations and limit the time for due diligence.
• Underwriters' deferred underwriting commissions ($17.5 million or up to $21.625 million) are contingent on completing a business combination, creating a potential conflict of interest.
• The company may pursue early-stage or financially unstable businesses, or entities lacking established revenue or earnings, which inherently carry higher risks.
• There is no requirement to obtain an independent fairness opinion unless combining with an affiliated entity, meaning public shareholders rely on the board's judgment.
• Litigation and Chapter 11 proceedings involving Bright Green Corp., a company founded and run by CEO Lynn Stockwell, and involving special advisor John Stockwell, could negatively impact the company's reputation and management's focus.
• The company's rights agreement and amended articles of association designate New York and Cayman Islands courts, respectively, as exclusive forums for certain disputes, potentially limiting shareholders' ability to choose a favorable judicial forum.
• The units may be worth less than those of other SPACs because each right converts into only one-tenth (1/10) of an ordinary share.

Risks

• No operating history, revenues, or identified target business, making it difficult to evaluate the ability to achieve business objectives.
• Public shareholders may not have an opportunity to vote on the proposed business combination, and even if a vote is held, founder shares will participate, potentially leading to approval without majority public shareholder support (only 4.5% of public shares needed for approval with minimum quorum).
• Inability to complete a business combination within the 24-month completion window, leading to liquidation and worthless rights.
• Potential for review by the Committee on Foreign Investment in the United States (CFIUS) if a U.S. business is targeted, which could block or delay the business combination.
• The ability of public shareholders to exercise redemption rights may make the company unattractive to potential target businesses or hinder meeting closing conditions.
• Intense competition from other SPACs and investment entities for attractive target businesses, potentially increasing acquisition costs or resulting in an inability to find a target.
• Changes in the market for directors and officers liability insurance could make it more difficult and expensive to negotiate and complete an initial business combination.
• Underwriters' deferred underwriting commissions, payable only upon completion of a business combination, may create potential conflicts of interest in rendering additional services.
• Initial shareholders, directors, officers, or affiliates may purchase shares or rights from public shareholders, which could influence a vote on a proposed business combination and reduce the public float.
• Acquisition opportunities may be sought with early-stage, financially unstable businesses, or entities lacking an established record of revenue or earnings, carrying inherent operational risks.
• Resources could be wasted researching acquisitions that are not completed.
• Lack of diversification if only one business combination is completed, subjecting the company to numerous economic, competitive, and regulatory risks of a single business.
• Risk of not properly ascertaining or assessing all significant risk factors of a particular target business due to limited time and resources.
• Failure of a shareholder to receive notice of redemption offers or to comply with tendering procedures may result in unredeemed shares.
• Public shareholders will not have any rights or interests in funds from the trust account, except under certain limited circumstances (redemption/liquidation).
• Nasdaq may delist the company's securities from trading, limiting investors' ability to make transactions and subjecting the company to additional trading restrictions.
• The company is not entitled to certain protections afforded to investors of Rule 419 blank check companies.
• Insufficient funds outside the trust account to operate until the end of the completion window, potentially leading to an inability to complete a business combination.
• If third parties bring claims against the company, the proceeds held in the trust account could be reduced, and the per-share redemption amount received by shareholders may be less than $10.00 per share.
• Directors may decide not to enforce the indemnification obligations of the sponsor, resulting in a reduction of funds in the trust account available for distribution.
• The securities in which funds held in the trust account are invested could bear a negative rate of interest, reducing the per-share redemption amount.
• If the company files for bankruptcy or winding-up, claims of creditors may have priority over shareholders, reducing the per-share amount received.
• The company may be deemed an investment company under the Investment Company Act, requiring burdensome compliance or restricting activities, making it difficult to complete a business combination.
• Past performance by the management team and their affiliates is not indicative of future performance.
• The company may seek acquisition opportunities outside of management's areas of expertise.
• Directors and officers will allocate their time to other businesses, causing conflicts of interest in their determination of time devoted to the company's affairs.
• The company is dependent upon its directors and officers, and their departure could adversely affect its ability to operate.
• Key personnel may negotiate employment or consulting agreements with a target business, potentially creating conflicts of interest.
• Limited ability to assess the management of a prospective target business, potentially leading to an initial business combination with management lacking skills for a public company.
• Conflicts of interest may arise from directors' and officers' affiliations with entities engaged in similar business activities, including other SPACs (e.g., DMAA).
• Litigation, investigations, or other proceedings involving members of the management team or board of directors (e.g., Bright Green Corp. Chapter 11 and lawsuit against John Fikany involving Lynn Stockwell and John Stockwell) could adversely affect the company.
• The nominal purchase price paid by the sponsor for founder shares results in significant dilution to the implied value of public shares and allows the sponsor to make a substantial profit even if the share price declines.
• The company may issue notes or other debt securities, or incur substantial debt, to complete a business combination, which may adversely affect leverage and financial condition.
• The share price of the combined company may decline after the initial business combination below the initial value of the units.
• The initial business combination and subsequent structure may not be tax-efficient to shareholders and rights holders, potentially resulting in unexpected tax liabilities.
• Reincorporation or transfer to another jurisdiction in connection with a business combination may result in taxes imposed on shareholders or rights holders.
• Cyber incidents or attacks directed at the company could result in information theft, data corruption, operational disruption, and/or financial loss.
• An investment may result in uncertain or adverse U.S. federal income tax consequences, including potential Passive Foreign Investment Company (PFIC) status.
• Changes to laws or regulations, or their interpretation (e.g., 2024 SPAC Rules), may adversely affect the business, including the ability to complete an initial business combination.
• Certain agreements related to the offering may be amended or waived without shareholder approval.
• Initial shareholders hold a substantial interest (20%), potentially exerting significant influence on actions requiring shareholder vote.
• The rights and founder shares may have an adverse effect on the market price of ordinary shares and make it more difficult to effectuate an initial business combination.
• The determination of the offering price of units and the size of the offering is more arbitrary than for an operating company.
• There is currently no market for the company's securities, and an active trading market may not develop.
• Difficulties in protecting interests and limited ability to protect rights through U.S. Federal or state courts due to incorporation under Cayman Islands law.
• The requirement to furnish target business financial statements may limit the pool of prospective target businesses.
• Compliance obligations under the Sarbanes-Oxley Act may make it more difficult and costly to effectuate an initial business combination.
• Pursuing a target business with operations or opportunities outside the United States may introduce additional burdens and risks.
• Management unfamiliarity with U.S. securities laws post-initial business combination could lead to regulatory issues.
• The company's results of operations and prospects could be significantly subject to economic, political, social, and government policies in the country of operation after the initial business combination.
• Recent increases in inflation could make it more difficult to complete an initial business combination.

Future Outlook

The company intends to identify, acquire, and accelerate the growth of a pharmaceutical business in the United States. The strategic focus is on mitigating U.S. medical supply chain risks by investing in strategic on-shoring of advanced domestic manufacturing technologies for critical drugs and active pharmaceutical ingredients (APIs). The goal is to create a fully integrated, competitive cost business with end-to-end capability from plant-based raw material production to drug manufacturing and direct patient delivery, targeting the estimated $44 billion plant-based production segment, API market, and generic medications. The company expects to incur increased expenses as a public company and will generate non-operating income from interest on trust account funds.

Management Comments

• "We have assembled a strong management team with a broad network of connections and corporate relationships across the pharmaceutical industry. We are confident that we will be able to use our individual experiences as well as our networks to achieve success."
• "Together, we will formulate an all-encompassing plan for growth, one that accounts for both organic expansion and expansion via mergers and acquisitions. In the end, we will attempt to transform our target company into a widely respected industry leader by leveraging the benefits of becoming a public company, including access to finance and equity for expansion. At the same time, we will endeavor to generate excellent returns for our shareholders."
• "We believe our management team is well positioned to take advantage of the growing set of investment opportunities focused on the pharmaceutical industry, and that our extensive existing relationships with portfolio companies along with our ongoing efforts to identify investment opportunities will allow us to generate an attractive transaction for our shareholders."
• "We believe that it is possible to mitigate risks in the U.S. medical supply chain by investing in companies that will reduce Americas overreliance on production of pharmaceuticals from concentrated geographic regions through investments in strategic on-shoring of advanced domestic manufacturing technologies for critical drugs."
• "We believe that we have an important role in the future of the pharmaceutical business. With a successful series of target acquisitions the result will be a fully integrated competitive cost business with vast expertise."
• "The aim will be for this business to have end-to-end capability from plant-based raw material production for a spectrum of controlled substances (the Active Pharmaceutical Ingredients (API)) to drug manufacturing and prescriptions filled by pharmacies or directly to the patients."
• "The post-business combination company would aim to grow revenues building on an addressable market for the estimated $44 billion plant-based production segment, API market, and generic medications."
• "As a full spectrum producer, the finished product would allow the post-business combination company to disrupt the current situation in the pharmaceutical market at a competitive cost while all operation from beginning of a product life-cycle to its end-user application are made in America."
• "The complete solution will aim to provide supply chain resilience while mitigating identified national health and security risks."
• "We believe that the deliverable of the post-business combination company over a lifecycle from seed to the finished generic drug, delivered to the pharmacy or patient directly, could mitigate an identified national security risk."
• "The business model will seek to guarantee production serviced by clean advanced technology leveraging artificial intelligence in controlled environments that are premised on advanced production technology in an energy efficient manner, while developing new continuous manufacturing processes for critical drugs and active pharmaceutical ingredients."
• "We believe that the post-business combination company will be able to become a new competitive cost producer of drugs made in America. Onboarding the production back to the USA creates jobs, mitigates national security risks and will ensure the American people will have clean, pure, cost-efficient medications through a resilient supply chain made in America."

Industry Context

The company aims to address critical issues in the U.S. medical supply chain, specifically the overreliance on foreign and geographically concentrated sources for medications and raw materials, which has led to persistent drug shortages. This strategy aligns with current administration initiatives to establish a fully integrated U.S. drug supply chain and reduce costs in finished generic drug production. The market for plant-based production, APIs, and generic medications is estimated at $44 billion, indicating a significant opportunity for a full-spectrum domestic producer. The company's focus on advanced technology, AI, and energy-efficient controlled environments for continuous manufacturing processes positions it to potentially disrupt the current market and enhance national healthcare security.

Comparison to Industry Standards

• The company is structured as a Special Purpose Acquisition Company (SPAC), a common vehicle for public market entry without traditional IPOs.
• The offering price of $10.00 per unit is standard for SPAC initial public offerings.
• The 24-month timeframe to complete a business combination is a typical duration for SPACs.
• The requirement to acquire a target with an aggregate fair market value of at least 80% of the trust account assets is a standard Nasdaq listing rule for SPACs.
• The dilution experienced by public shareholders due to founder shares acquired at a nominal price is a common characteristic of SPACs, often leading to significant dilution for public investors.
• The management team's involvement in multiple SPACs (e.g., Drugs Made In America Acquisition Corp. DMAA) is a known conflict of interest structure in the SPAC industry.
• The use of a trust account for proceeds and redemption rights for public shareholders are standard SPAC features designed to protect investors.
• The deferred underwriting commissions, payable only upon a successful business combination, are a standard incentive structure for underwriters in SPACs.

Management Changes

Corporate Governance

Legal Proceedings

• Bright Green Corp. (BGXX), a company founded and run by CEO Lynn Stockwell, entered into a Restructuring Support Agreement on January 27, 2025, and filed a voluntary Chapter 11 petition on February 22, 2025. BGXX shares were suspended from trading on Nasdaq in September 2024.
• In January 2021, BGXX filed a complaint against John Fikany; a court determined in August 2024 that an oral agreement existed for Fikany to be CEO and BGXX was not entitled to cancel his 5,000,000 shares. BGXX plans to appeal and file motions opposing Fikany's claims in the Chapter 11 proceeding. John Stockwell (special advisor and Lynn Stockwell's husband) was also a third-party defendant in this counterclaim.

Related Party Transactions

• The sponsor (Drugs Made In America Acquisition II LLC), of which Lynn Stockwell is the sole member, purchased 14,375,000 founder shares for a nominal price of $35,000 (approximately $0.0024 per share).
• The sponsor and Cantor Fitzgerald & Co. committed to purchase 1,200,000 private units for $12,000,000 ($10.00 per unit) in a private placement that will close simultaneously with the IPO.
• The company will pay the sponsor or an affiliate $10,000 per month for office space, administrative, and support services.
• The company will repay up to $325,000 in loans made by the sponsor to cover offering-related and organizational expenses; $250,100 was outstanding as of March 31, 2025.
• Up to $1,500,000 in working capital loans from the sponsor or an affiliate, or certain directors and officers, may be convertible into private units at $10.00 per unit.
• The company's CFO, Glenn Worman, is a partner in an advisory firm that provides accounting services to the company, incurring $6,283 in expenses for the three months ended March 31, 2025.
• Lynn Stockwell is married to John Stockwell, who serves as a special advisor without compensation but may receive reasonable reimbursements for routine expenses. He holds no interest in the company's securities other than through Lynn Stockwell's interests.
• All officers and directors currently serve as officers and directors of Drugs Made In America Acquisition Corp. (DMAA), another SPAC, creating pre-existing fiduciary obligations to DMAA.

Stakeholder Impact

• Shareholders: Public shareholders face significant dilution from founder shares and the risk of losing their investment if a business combination is not completed. They have redemption rights under specific conditions. Initial shareholders (sponsor, management) hold substantial influence and have the potential for significant profit even if the share price declines.
• Employees: The company's strategy to on-shore pharmaceutical production in the U.S. could lead to job creation in the domestic market. Management and key personnel of any acquired target business may remain with the combined entity.
• Customers/Suppliers: The focus on a resilient U.S. drug supply chain aims to provide cost-efficient and pure medications, potentially benefiting customers and fostering domestic supplier relationships.
• Creditors: Funds in the trust account are generally protected from third-party claims, but there is a risk if waivers are unenforceable or in bankruptcy proceedings. The sponsor has indemnification obligations to protect the trust account.
• Regulatory Bodies: The company is subject to SEC and Nasdaq regulations. Its business strategy aligns with U.S. government initiatives for drug supply chain security, potentially garnering regulatory support for its mission.

Next Steps

• Complete the initial public offering of 50,000,000 units.
• Deposit $500,000,000 (or $575,000,000 if over-allotment exercised) into a U.S.-based trust account.
• Apply to list units on The Nasdaq Global Market (DMIIU) on or promptly after the prospectus date.
• Begin separate trading of ordinary shares (DMII) and rights (DMIIR) on the 52nd day following the prospectus date (or earlier if Cantor allows), subject to filing a Form 8-K.
• Identify potential acquisition targets in the pharmaceutical industry.
• Conduct due diligence on prospective target businesses.
• Negotiate and consummate an initial business combination within 24 months from the closing of the offering.
• If no business combination is completed within 24 months, redeem public shares and liquidate.
• Establish and maintain an audit committee and compensation committee.
• Adopt a compensation recovery policy compliant with Nasdaq listing rules.
• Adopt a Code of Conduct.
• File annual, quarterly, and current event reports with the SEC as a public company.
• Comply with internal control reporting requirements of the Sarbanes-Oxley Act for the fiscal year ending December 31, 2025.

Key Dates

Keywords

SPAC, blank check company, pharmaceutical industry, IPO, business combination, M&A, U.S. drug supply chain, domestic manufacturing, active pharmaceutical ingredients (API), generic drugs, corporate governance, risk management, SEC filing, S-1, Cayman Islands, Nasdaq, Lynn Stockwell, Glenn Worman, Bright Green Corporation